InMode Ltd. $INMD Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC grew its holdings in InMode Ltd. (NASDAQ:INMD) by 187.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,530 shares of the healthcare company’s stock after acquiring an additional 33,575 shares during the quarter. Lazard Asset Management LLC owned 0.08% of InMode worth $705,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Leonteq Securities AG acquired a new position in shares of InMode during the fourth quarter valued at about $26,000. Quadrant Capital Group LLC boosted its stake in InMode by 127.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after purchasing an additional 1,091 shares in the last quarter. Advisory Services Network LLC purchased a new stake in InMode during the 3rd quarter worth approximately $37,000. Basepoint Wealth LLC purchased a new stake in InMode during the 4th quarter worth approximately $39,000. Finally, Deutsche Bank AG increased its stake in InMode by 35.9% during the 4th quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company’s stock valued at $58,000 after purchasing an additional 1,037 shares in the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Stock Down 1.0%

InMode stock opened at $15.21 on Thursday. The stock has a 50-day moving average price of $14.47 and a 200 day moving average price of $14.24. The company has a market capitalization of $874.27 million, a price-to-earnings ratio of 11.18 and a beta of 1.89. InMode Ltd. has a 52 week low of $12.72 and a 52 week high of $16.74.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Thursday, August 6th. The healthcare company reported $0.35 earnings per share for the quarter, hitting the consensus estimate of $0.35. InMode had a net margin of 23.27% and a return on equity of 13.47%. The company had revenue of $95.59 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter in the prior year, the company earned $0.47 EPS. InMode’s quarterly revenue was up .0% on a year-over-year basis.

Analyst Ratings Changes

A number of research analysts have issued reports on INMD shares. Barclays set a $19.00 price target on shares of InMode and gave the stock an “overweight” rating in a report on Thursday, May 7th. Robert W. Baird cut their target price on InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, InMode currently has a consensus rating of “Hold” and an average target price of $16.00.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.